Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
10.1159/000503713
Saved in:
Main Authors: | Bakris, George L, Agarwal, Rajiv, Anker, Stefan D, Pitt, Bertram, Ruilope, Luis M, Nowack, Christina, Kolkhof, Peter, Ferreira, Anna C, Schloemer, Patrick, Filippatos, Gerasimos, FIGARO-DKD investigators |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Language: | English |
Published: |
KARGER
2023
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/246026 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes
by: Filippatos, Gerasimos, et al.
Published: (2022) -
IMPORTANCE OF IDENTIFYING UNILATERAL, SURGICALLY-CURABLE PRIMARY ALDOSTERONISM
by: PUAR HAI KIAT
Published: (2023) -
Healthcare Challenges in the Management of Primary Aldosteronism in Southeast Asia
by: Hai Kiat Puar
Published: (2023) -
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
by: Pitt, Bertram, et al.
Published: (2023) -
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
by: George L. Bakris, et al.
Published: (2022)